Acrivon Therapeutics Inc (ACRV)
8.88
+0.32
(+3.74%)
USD |
NASDAQ |
May 17, 16:00
8.88
0.00 (0.00%)
After-Hours: 20:00
Acrivon Therapeutics Shareholders Equity (Quarterly): 107.98M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 107.98M |
| December 31, 2023 | 121.20M |
| September 30, 2023 | 138.15M |
| June 30, 2023 | 149.18M |
| March 31, 2023 | 160.47M |
| Date | Value |
|---|---|
| December 31, 2022 | 170.48M |
| September 30, 2022 | -45.62M |
| June 30, 2022 | -36.58M |
| December 31, 2021 | -23.81M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-45.62M
Minimum
Sep 2022
170.48M
Maximum
Dec 2022
82.38M
Average
121.20M
Median
Dec 2023
Shareholders Equity (Quarterly) Benchmarks
| MyMD Pharmaceuticals Inc | 12.37M |
| Vincerx Pharma Inc | -0.622M |
| GlycoMimetics Inc | 28.91M |
| Immunic Inc | 83.58M |
| Skye Bioscience Inc | 78.88M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 120.52M |
| Total Liabilities (Quarterly) | 12.54M |